Voyageur Financial Statements From 2010 to 2024

VM Stock  CAD 0.06  0.01  10.00%   
Voyageur Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Voyageur Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Voyageur Pharmaceuticals financial statements helps investors assess Voyageur Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Voyageur Pharmaceuticals' valuation are summarized below:
Market Capitalization
7.7 M
Earnings Share
(0.01)
There are over one hundred nineteen available fundamental trend indicators for Voyageur Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should should double-check Voyageur Pharmaceuticals' current fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to drop to about 4.1 M in 2024. Enterprise Value is likely to drop to about 4 M in 2024
Check Voyageur Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Voyageur Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 703.5 K, Other Operating Expenses of 779.8 K or Total Operating Expenses of 779.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.14. Voyageur financial statements analysis is a perfect complement when working with Voyageur Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Voyageur Pharmaceuticals Technical models . Check out the analysis of Voyageur Pharmaceuticals Correlation against competitors.

Voyageur Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.6 M2.5 M1.2 M
Slightly volatile
Total Current Liabilities418.5 K775 K409.3 K
Slightly volatile
Cash1.8 K1.9 K174.5 K
Pretty Stable
Cash And Short Term Investments1.8 K1.9 K174.5 K
Pretty Stable
Net Receivables35.5 K41.3 K31.1 K
Slightly volatile
Common Stock Shares Outstanding157.6 M150.1 M57.2 M
Slightly volatile
Liabilities And Stockholders Equity2.6 M2.5 M1.2 M
Slightly volatile
Total Liabilities484.9 K837.1 K470.2 K
Slightly volatile
Total Current Assets96.8 K101.9 K244.7 K
Very volatile
Property Plant And Equipment Net6.4 K6.7 K576.5 K
Slightly volatile
Accounts Payable238251247.9 K
Pretty Stable
Non Current Assets Total1.3 M2.4 M967.9 K
Slightly volatile
Other Current Assets61.2 K87.7 K43.7 K
Slightly volatile
Common Stock10.5 M10 M3.7 M
Slightly volatile
Property Plant Equipment974.4 K1.9 M861.7 K
Slightly volatile
Other Liabilities12 K12.6 K142.7 K
Slightly volatile
Non Current Liabilities Total46.2 K48.6 K172.2 K
Slightly volatile
Short and Long Term Debt Total34.2 K36 K74.2 K
Very volatile
Short and Long Term Debt133.6 K240.3 K118 K
Slightly volatile
Short Term Debt18.1 K19 K32.7 K
Pretty Stable
Long Term Debt41.4 K36 K88.8 K
Slightly volatile
Capital Stock5.7 M10 M4.2 M
Slightly volatile
Property Plant And Equipment Gross1.9 M2.4 M1.5 M
Slightly volatile
Short Term Investments4.13.155.4767
Slightly volatile
Non Current Liabilities Other0.80.90.98
Slightly volatile

Voyageur Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative703.5 K432.6 K557.7 K
Slightly volatile
Other Operating Expenses779.8 K1.5 M728 K
Slightly volatile
Total Operating Expenses779.6 K1.5 M727.7 K
Slightly volatile
Depreciation And Amortization1.9 KK226.9 K
Slightly volatile
Selling And Marketing Expenses145.3 K252.8 K115.9 K
Very volatile
Reconciled Depreciation3.8 K2.5 K2.7 K
Slightly volatile

Voyageur Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities900.1 K1.3 M758.6 K
Slightly volatile
End Period Cash Flow1.8 K1.9 K174.5 K
Pretty Stable
Stock Based Compensation247.7 K269.1 K177.1 K
Slightly volatile
Begin Period Cash Flow34.5 K36.3 K143 K
Very volatile
Sale Purchase Of Stock1.1 MM582.1 K
Slightly volatile
Other Cashflows From Investing Activities0.860.938.3 K
Pretty Stable
Depreciation3.4 K2.5 K2.7 K
Slightly volatile
Issuance Of Capital Stock1.2 M1.4 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables11.2 K11.8 K273.7 K
Slightly volatile
Capex To Depreciation66.171.9737.2058
Slightly volatile
Payables Turnover0.690.72371.2008
Pretty Stable
Average InventoryKK9.8 K
Slightly volatile
Cash Per Share0.730.69190.2072
Pretty Stable
Days Payables Outstanding47950474.6 K
Slightly volatile
Current Ratio19.1718.25277.4607
Very volatile
Graham Number0.930.88190.3368
Pretty Stable
Capex Per Share0.170.16240.0418
Slightly volatile
Average Receivables5.9 K6.2 K32.7 K
Slightly volatile
Interest Debt Per Share3.0E-44.0E-40.0014
Pretty Stable
Debt To Assets0.02020.02130.0619
Pretty Stable
Days Of Payables Outstanding47950474.6 K
Slightly volatile
Ebt Per Ebit0.790.941.015
Slightly volatile
Quick Ratio19.5918.65627.5667
Very volatile
Dividend Paid And Capex Coverage Ratio0.20.214325.0441
Very volatile
Net Income Per E B T0.80.90.98
Slightly volatile
Cash Ratio18.8317.93557.1381
Very volatile
Free Cash Flow Operating Cash Flow Ratio5.955.66642.4003
Slightly volatile
Capital Expenditure Coverage Ratio0.20.214325.0441
Very volatile
Debt Ratio0.02020.02130.0619
Pretty Stable

Voyageur Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.1 M4.7 M4.2 M
Slightly volatile
Enterprise ValueM4.7 M4.2 M
Slightly volatile

Voyageur Fundamental Market Drivers

Cash And Short Term Investments2085.00

About Voyageur Pharmaceuticals Financial Statements

Voyageur Pharmaceuticals investors use historical fundamental indicators, such as Voyageur Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Voyageur Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue22.9 K24 K
Cost Of RevenueK1.9 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Voyageur Stock Analysis

When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.